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Abstract
The precise mechanism whereby granulocytes prolifer-
ate when haematopoietic colony stimulating factors (CSFs)
are used in neutropenic cancer patients is poorly under-
stood. The purpose of this study was to investigate
whether these cytokines bring about leucocyte prolifera-
tion by increasing the levels of multiple forms of dihy-
drofolate reductase (DHFR). Blood samples were col-
lected from 36 cancer patients (25 males and 11 females)
with chemotherapy-induced neutropenia. One sample of
blood from each patient was obtained before therapy
either with CSF, such as granulocyte colony stimulating
factor (G-CSF) and granulocyte-macrophage colony sti-
mulating factor (GM-CSF) or with placebo, and another
one at the time of resolution of neutropenia. Peripheral
blood leucocytes in these blood samples were counted,
separated and lysed. From lysates, cytoplasmic samples
were prepared and analyzed for active DHFR by a
methotrexate-binding assay and for total immunoreac-
tive DHFR by an enzyme linked immunosorbent assay.
The increase in total leucocyte count (TLC) was most
prominent (P < 0.005) in the CSF group and less so
(P < 0.05) in the placebo group. The mean ± SD
concentration values of active DHFR before and after
stimulation with GM-CSF found were to be 0.34 ± 0.4
ng/mg protein and 0.99 ± 0.82 ng/mg protein, respec-
tively, and in the group treated with G-CSF, 0.24 ± 0.32
ng/mg protein and 1.18 ± 2.4 ng/mg protein, respectively.
This increase in active DHFR after stimulation with CSF
was statistically significant (P < 0.05). Similarly, concent-
ration values of immunoreactive but nonfunctional form of
DHFR (IRE) were 110 ± 97 ng/mg protein and 605 ± 475
ng/mg protein before and after stimulation with GM-
CSF, and 115 ± 165 ng/mg protein and 1054 ± 1095 ng/
mg protein before and after stimulation with G-CSF. This
increase in concentration of IRE after stimulation with
GM-CSF or G-CSF was statistically significant (P < 0.005).
In the control group, there was an increase in the
concentration of both active DHFR and IRE after treat-
ment with placebo. However, this was not statistically
significant. Resolution of neutropenia was quicker in the
groups treated with CSF compared to the control group.
Results of this study indicate that colony stimulating
factors (G-CSF and GM-CSF) induce white cell prolife-
ration by increasing the levels of multiple forms of DHFR.
Keywords: Dihydrofolate reductase, neutropenia, colony
stimulating factor, granulocyte colony stimulating factor,
granulocyte-macrophage colony stimulating factor, im-
munoreactive nonfunctional form.
Introduction
Haematopoietic colony-stimulating factors (CSFs), granu-
locyte colony-stimulating factor (G-CSF) and granulocy-
te-macrophage colony-stimulating factor (GM-CSF) are
now increasingly used to overcome the cytopenic side
effects of chemotherapy (Vose et al., 1995; Raval et al.,
1998). The mechanism by which these cytokines induce
proliferation of progenitor cells is poorly understood.
Dihydrofolate reductase (DHFR) is a key enzyme in
the de novo pathway of DNA synthesis (Dunlap et al.,
1971) and therefore has a role in cell proliferation. In
addition to the active form of enzyme, other molecular
forms of this enzyme having low affinity to bind to
methotrexate have been identified in murine leukemia
cells (Dedhar and Goldie, 1983) and goat liver (Iqbal et
al., 1987). Moreover, immunologically distinct and func-
tionally inactive forms of this enzyme have also been
reported to be present in human leukemia cells and
leucocytes of cancer patients (Iqbal and Rothenberg,
1981; Rothenberg and Iqbal, 1982; Iqbal et al., 1992;
Iqbal et al., 1997). The concentration of this immuno-
reactive nonfunctional form of DHFR has been found to
be greatly increased in cells during their log growth
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compared to the stationary growth phase (Rothenberg
and Iqbal, 1983) suggesting that this form of enzyme
may also be having a role in cell proliferation. Studies in
vitro
 have demonstrated that resting cells can be stimu-
lated to re-enter the cell cycle through the addition of a
factor in serum, which also causes increased expres-
sion of DHFR gene (Johnson et al., 1978).
The present study was undertaken to investigate
whether CSFs induce white cell proliferation in neutro-
penic patients by increasing the levels of multiple forms
of DHFR.
Materials and Methods
The data were collected prospectively between October
1997 and January 1999. Patients admitted to the Hae-
matology/Oncology services at The Aga Khan Univer-
sity Hospital with chemotherapy-induced febrile neutro-
penia were the subjects of this study. Neutropenia was
defined as an absolute neutrophil count (ANC) of less
than 500/µl. For the purpose of current analysis, only
those patients were included whose blood samples
were available both at the time of the diagnosis and
upon resolution of neutropenia. The patients received
antibiotics, if they were febrile, or followed up if they
were afebrile.
Ten ml of blood was removed in a heparinized tube for
estimation of multiple forms of DHFR. The patients were
treated with either GM-CSF, (Molgrastim, Novartis, Basel,
Switzerland) at a dose of 250 µg/m2/day or G-CSF
(Filgrastim, Roche, Basel, Switzerland) at a dose of 5
µg/kg/day. Blood samples were also obtained from
patients who were treated with placebo (normal saline).
The CSF was administered daily and the total leuco-
cytes count (TLC) was also checked daily. The CSFs
were stopped once the ANC was more than 500/µl. The
second sample of 10 ml of blood was obtained in a
heparinized tube upon resolution of neutropenia.
White blood cells were removed from the blood sample
using 3% dextran and cytoplasms of these samples were
prepared as described previously (Rothenberg and Iqbal,
1982). These cytoplasmic samples were analyzed for
active DHFR by using methotrexate-binding assay
(Rothenberg et al., 1977) and for total immunoreactive
DHFR by enzyme-linked immunosorbent assay (Iqbal
and Hussain, 1991) using antiserum that had previously
been defined (Rothenberg and Iqbal, 1982). The con-
centration of immunoreactive but nonfunctional form of
DHFR (IRE) in these cytoplasmic samples was obtained
by subtracting the concentration value of active DHFR
from the value of total immunoreactive DHFR. The
protein concentration was determined by the method of
Lowry et al. (1951). The full blood count was checked
on a Coulter Counter. Differential white cell count was
obtained by manual counting.
The data are expressed as means ± SD. Statistical
analysis of the data was carried out by using Students
t-test. The level of statistical significance was P < 0.05
(two-tailed comparison).
Results
Characteristics of 36 patients involved in this study are
listed in Table 1. There was an unequal distribution of
patients within the three groups (namely, GM-CSF treat-
ed group, G-CSF treated group and the placebo treated
group). This was because the patients were not rando-
mized prospectively. Also, patients whose subsequent
samples were not available on time were excluded. These
included patients who died during the neutropenic phase.
Total leucocytes count and mean concentration values
of active DHFR and IRE in leucocyte cytoplasmic sam-
ples of neutropenic cancer patients before and after
Table 2. Total leucocyte count and concentration values of active DHFR and immunoreactive nonfunctional DHFR (IRE) in leucocyte cytoplasm samples of
neutropenic cancer patients before and after stimulation with CSFs or placebo (means ± SD)
Subjects 
(treatment)
No
(n)
Active DHFR 
(ng/mg protein)
IRE (ng/mg protein) Total leucocyte count 
(cells × 109/l)
Time for resolution 
of neutropenia 
(days)Before After Before After Before After
GM-CSF 10 0.31 ± 0.40 0.99 ± 0.82* 110 ± 970 605 ± 475** 0.5 ± 0.25 04.1 ± 3.11** 6.3 ± 2.7
G-CSF 19 0.24 ± 0.32 1.18 ± 2.4* 115 ± 165 1054 ± 1095** 0.9 ± 0.67 11.8 ± 12.9** 5.0 ± 2.4
Placebo 7 0.75 ± 0.73 1.93 ± 2.37 216 ± 135 722 ± 6220 0.7 ± 0.43 3.43 ± 2.93* 9.1 ± 5.4
*As compared with the value before treatment P < 0.05 (Students t-test), **As compared with the value before treatment P < 0.005 (Students t-test).
Table 1. Characteristics of patients treated with GM-CSF, G-CSF and
controls
Control GM-CSF G-CSF
Age (mean ± SD years) 24.3 ± 12.7 29.8 ± 9.6 35.8 ± 18
Sex (male : female) 2:5 8:2 15:4
Underlying diagnosis:
Acute myelogenous leukaemia 2 4 4
Acute lymphocytic leukaemia 2 2 3
Non-Hodgkins lymphoma 1 1 5
Solid tumors 2 3 7
Total 7 10 19
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stimulation with CSF or placebo are shown in Table 2.
There was nearly a three-fold rise in the level of active
DHFR following stimulation with GM-CSF and five-fold
rise following stimulation with G-CSF. The increase was
statistically significant (P < 0.05). Although there was
some rise in the concentration of active DHFR in the
placebo group, this was not statistically significant. Simi-
larly, there was a significant increase (P < 0.005) in the
levels of IRE following stimulation with both GM-CSF
and G-CSF, but the increase in the placebo-treated
group was not significant. As seen in the Table 2, the
neutropenia resolved completely in the three groups.
The mean duration of resolution of neutropenia was
also studied (Table 2). Neutropenia resolved in the G-
CSF treated group in 5 ± 2.4 days, 6.3 ± 2.7 days in the
GM-CSF treated group and in 9.1 ± 5.4 days in the
control group.
Discussion
The mechanism by which CSFs induce cell proliferation
is complex and not fully defined as yet, especially at the
nuclear level (Cambronero and Veatch, 1996). Since
DHFR has a key role in cell proliferation, it could be one
of the enzymes influenced by CSFs. We have previ-
ously reported an immunoreactive but nonfunctional
form of DHFR, which is abundantly present in human
normal and cancer cells (Rothenberg and Iqbal, 1982;
Iqbal et al., 1992; Iqbal et al., 1997). This has not only
been identified in human leukaemia cells but also in
leucocytes of cancer patients and in normal colon as
well as in colonic tumor tissues (Iqbal et al., 1992).
However, the concentration of this immunoreactive non-
functional form of enzyme (IRE) in human colon cyto-
plasm samples was nearly one tenth those of leukaemia
cells suggesting that cells with greater proliferative
potential may have a higher concentration of this pro-
tein. Gel filtration chromatography of this protein reveal-
ed heterogeneity of its size and a major fraction of the
protein had a size larger than the active DHFR. This
large immunoreactive protein could be partially dissoci-
ated into a protein of the size of DHFR by treatment with
8 M urea and 40 mM dithioerythreitol (Iqbal et al., 1992).
However, the resulting protein failed to show any activity
of DHFR. Since this protein is abundantly present in
leucocytes of cancer patients (Iqbal et al., 1992) it is
plausible that it might also increase along with active
DHFR as a result of treatment with CSFs. Our preli-
minary data suggested that there may be an association
between CSFs, multiple forms of DHFR and white cell
count (Iqbal et al., 1998). How these could be related is
still conjectural but one possible link between the CSF,
DHFR and cell proliferation could be through the ex-
pression of certain oncogenes functioning as transcrip-
tional factors, such as, c-myc.
Several studies have shown that c-myc expression is
closely linked with the expression of DHFR gene (Mai,
1994; Lucke-Huhle et al., 1997) and cell proliferation
(Mai and Jalava, 1994). Cambronero and Veatch (1996)
have also indicated the involvement of c-myc in the GM-
CSF signaling pathway. Germolec et al. (1996) have re-
ported increased cell proliferation along with increased
expression of c-myc gene and increased transcription of
GM-CSF as a result of arsenic treatment, again depict-
ing an association between cell proliferation, c-myc and
GM-CSF. In view of the above-mentioned reports, it
would be plausible to assume a close relationship among
CSFs (especially GM-CSF), DHFR, and white blood cells
proliferation.
Our results indicate that there was a significant rise in
both active DHFR and IRE in the GM-CSF and G-CSF
treated groups. Although there was some increase in
the levels of two forms of DHFR in the placebo-treated
group but this did not reach significance. GM-CSF and
G-CSF are endogenously produced cytokines, the prod-
uction of which is increased during neutropenia (Cairo et
al., 1992). It is possible that the small rise in the levels
of multiple forms of DHFR in the control group may be
due to the increased endogenous production of these
cytokines.
We are mindful of some of the limitations of this study.
The age distribution of patients is unequal in three groups.
This is because patients were not randomized prospec-
tively to receive either GM-CSF or G-CSF or placebo.
Instead, samples were collected for analysis of DHFR in
a non-random fashion. A few patients died during the
phase of neutropenia and a second sample was not
available for enzyme estimation. These patients were
excluded.
The various underlying cancers were also unequally
distributed among the three groups. This may affect the
duration of neutropenia, which is usually longer in the
myeloid malignancies (Talcott et al., 1992). However,
there were 4 patients each with AML in the GM-CSF
and G-CSF treated groups and only two patients in the
placebo-treated group. If there were more patients in
this group this would have resulted in a further increase
in the duration of neutropenia.. However, the aim of this
study was not to compare the duration of neutropenia
among different treatment groups. Within each group,
despite resolution of neutropenia, the multiple forms of
DHFR significantly increased only in the GM-CSF and
G-CSF treated groups.
Another limitation is that although the study included
neutropenic patients only (ANC < 500/µl), the results are
expressed as TLC. The cells were separated using 3%
dextran and no further attempt was made to separate
neutrophils. However, following chemotherapy, it is the
neutrophil count, which declines and is resolved quickly
upon stimulation with CSFs or over time. The increase
in the levels of multiple forms of DHFR in leucocytes,
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therefore, reflects an increase of this enzyme mainly in
neutrophils.
Our data clearly show that induction of white cell
proliferation, after treatment with G-CSF or GM-CSF is
accompanied by increased levels of multiple forms of
DHFR. However, at the present moment we are not
sure whether the increase in levels of multiple forms of
DHFR is due to an induction of these forms of enzyme
or through increased stabilization of the transcripts (Leys
et al.,
 1984). In vitro studies to quantitate the mRNA for
DHFR in myeloid precursor cells in presence and
absence of CSFs will help for further elucidation of the
role DHFR might be playing in the induction of white cell
proliferation.
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